NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b-Reference-Cited by-同舟云学术

NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b

Published:2016-12-02 Issue:7 Volume:52 Page:845-854
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Ogawa Eiichi, ,Furusyo Norihiro,Nomura Hideyuki,Dohmen Kazufumi,Higashi Nobuhiko,Takahashi Kazuhiro,Kawano Akira,Azuma Koichi,Satoh Takeaki,Nakamuta Makoto,Koyanagi Toshimasa,Kato Masaki,Shimoda Shinji,Kajiwara Eiji,Hayashi Jun

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/article/10.1007/s00535-016-1290-1/fulltext.html

Reference21 articles.

1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53:39–43.

2. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.

3. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–13.

4. Furusyo N, Kajiwara E, Takahashi K, et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol. 2008;23:1094–104.

5. Ogawa E, Furusyo N, Kajiwara E, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol. 2012;27:1233–40.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication;Journal of Medical Virology;2022-06-11

2. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

3. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral;Global Health & Medicine;2021-10-31

4. Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy;PeerJ;2021-09-17

5. Efforts to identify HCV antibody-positive patients in a medium-sized hospital by "Team hepatitis" composed of hospital staff with a hepatitis medical care coordinator;Kanzo;2021-06-01